On 10 August 2026 the MHRA granted a UK marketing authorisation for orforglipron (brand name Foundayo) for weight management and type 2 diabetes — the first approval of this GLP-1 tablet in Europe. In plain terms, that means the medicine has met the UK regulator's standards to be prescribed here; it does not mean any given pharmacy stocks it, that the NHS funds it, or that a UK price exists yet.
That distinction — authorisation versus availability — is the single most misunderstood point in the current coverage. This article explains exactly what changed on 10 August, what did not, and how to read the news accurately.
What a UK marketing authorisation actually is
A marketing authorisation (sometimes called a licence) is a formal decision by the Medicines and Healthcare products Regulatory Agency (MHRA). It confirms that, based on the evidence submitted, a medicine's quality, safety and efficacy are acceptable for its intended use.
Once a medicine holds an authorisation, it can legally be prescribed and supplied in the UK for the licensed indication. Before that point, it generally cannot be prescribed as a standard licensed medicine at all.
So the authorisation of orforglipron is a genuine regulatory milestone. It is the step that permits the medicine to enter UK clinical use — but permission and presence are two different things.
Why authorisation is not the same as availability
A marketing authorisation is a legal permission. It is not a guarantee that manufacturing supply reaches the UK in volume, that individual pharmacies choose to dispense it, or that the NHS agrees to pay for it.
Several separate things all have to happen after authorisation before a patient can realistically obtain a medicine:
- Manufacturer supply — the company must actually distribute stock into the UK market.
- Pharmacy decisions — each pharmacy or clinic independently decides whether to source and dispense it.
- Pricing — a UK list price has to be published for private supply.
- NHS funding — a completely separate NICE appraisal decides whether the NHS pays for it, and on what terms.
None of these follow automatically from an MHRA licence. This is why a medicine can be "authorised" for months before it is widely obtainable — and why headlines about approval can create a misleading impression of immediate access.
Where things stand for orforglipron in the UK
Here is what can be stated factually as of the authorisation date:
- Orforglipron was FDA approved in the United States on 1 April 2026.
- The MHRA granted a UK marketing authorisation on 10 August 2026 for weight management and type 2 diabetes.
- There is no published UK price for orforglipron at this time.
- There is no confirmed NICE timetable or NHS funding date. NHS funding is a separate decision from the MHRA licence and has not been confirmed.
Rather than estimate a UK price or a launch date, the honest position is simply that neither has been published. You can read our factual reference page on Foundayo (orforglipron) for the details we can verify.
Please note: We do not supply orforglipron yet — we intend to offer it once we are able to obtain it. This article is neutral, factual information, not a product offer, and we cannot give a date because that depends on wholesaler supply.
How orforglipron works
Orforglipron is a small-molecule GLP-1 receptor agonist. GLP-1 is a natural gut hormone involved in appetite and fullness, and medicines in this class mimic its effect so you tend to feel satisfied sooner and for longer.
What makes orforglipron unusual is that it is a small molecule designed to survive digestion. That allows it to be taken as an ordinary once-daily pill, at any time of day, with or without food or water.
That is a different practical profile from oral semaglutide, which must be taken on an empty stomach with strict timing rules — see our page on the Wegovy Tablet for how those rules work in practice.
What the trial data shows
In the Phase 3 ATTAIN-1 trial, participants on the 36mg dose lost on average 12.4% of their body weight over 72 weeks, alongside lifestyle counselling. Individual results vary; not everyone reaches this.
This is a single trial figure and is not a head-to-head comparison against any other medicine.
Options that are available now
While orforglipron sits at the authorisation-only stage, several MHRA-licensed weight-management medicines are already prescribable in the UK through a proper clinical route. These include:
| Medicine | Form | From |
|---|---|---|
| Mounjaro (tirzepatide) | Weekly injection | £160/month |
| Wegovy injection (semaglutide) | Weekly injection | £115/month |
| Wegovy Tablet (oral semaglutide) | Daily tablet | £115/month |
You can see the full range on our treatments overview and compare the injectable options on our weight-loss injections page.
Who these medicines may suit
Eligibility for licensed weight-management medicines is broadly consistent. They are generally considered for adults aged 18 and over with a BMI of 30 or more, or a BMI of 27–30 alongside a weight-related condition such as type 2 diabetes, high blood pressure or sleep apnoea.
They are not suitable for everyone. They are not used in pregnancy, when planning pregnancy or breastfeeding, in type 1 diabetes, or where there is a personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, severe gastrointestinal disease, an active eating disorder, severe liver or kidney impairment, or a known allergy to the active ingredient.
These are Prescription-Only Medicines. They are available only after a clinical consultation with a GPhC-registered prescriber, and a prescription is issued only if it is clinically appropriate — treatment is never guaranteed.
Side effects to be aware of
GLP-1 medicines share a common side-effect profile. The most common effects (affecting more than 1 in 10 people) include nausea, diarrhoea, constipation, vomiting, decreased appetite and fatigue.
Rare but serious effects can include severe allergic reaction, acute pancreatitis, severe hypoglycaemia and severe gastrointestinal disease. If you experience a side effect, you can report it to the MHRA at https://yellowcard.mhra.gov.uk/.
The bottom line
The MHRA authorising orforglipron is real and significant — it clears the regulatory hurdle that allows the medicine to be prescribed in the UK. But authorisation is a permission, not a delivery. Supply, pricing and NHS funding are separate steps, and none of them have a confirmed UK position yet.
If you want to explore treatments that are available now, you can start with our free online consultation to check whether treatment may be clinically appropriate for you. You can also read more about The Weight Clinic or browse our blog for further explainers.
This article is for information only and is not a substitute for personalised medical advice. Weight-loss medicines are prescription-only, are not suitable for everyone, and are prescribed only after a clinical consultation with a GPhC-registered prescriber. Individual results vary. Always speak to a UK-registered pharmacist or doctor before starting or changing any prescription medication.
